ICW-C3-1  Prevalence of comorbidities for patients with rheumatoid arthritis: A nationwide cross-sectional study  
**Chien-Chang Liao**  
School of Medicine, Taipei Medical University, Taipei, Taiwan

ICW-C3-2  Health Care Utilization Associated with Adverse Events among RA Patients Treated by TNF-alpha in Taiwan  
**Hsiao-Ling Kuo**  
Division of Rheumatology and Immunology, Mackay Memorial Hospital, Hsinchu, Taiwan

ICW-C3-3  Methotrexate toxicity among Filipino patients with rheumatoid arthritis included in the Rheumatoid Arthritis Database and Registry (RADAR)  
**Eliza Mia M Dejoras**  
Section of Rheumatology, Department of Medicine, UP-Philippine General Hospital, Philippines

ICW-C3-4  Assessment of peripheral blood subsets related to spontaneous regression of Methotrexate associated lymphoproliferative disorder (MTX-LPD)  
**Shuntaro Saito**  
Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan

ICW-C3-5  Pulmonary barrier function rather than systemic immune state is crucial for the development and exacerbation of non-tuberculous mycobacterial (NTM) infection in patients with rheumatic diseases  
**Sayaka Takenaka**  
Division of Rheumatology, Toho University Ohashi Medical Center, Japan

ICW-C3-6  A risk analysis of Pneumocystis pneumonia in patient with rheumatoid arthritis by the National Database of Rheumatic Diseases by iR-net in Japan  
**Takahiro Nunokawa**  
Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan

ICW-C3-7  Possible preventive effect of salazosulfapyridine against development of *Pneumocystis* pneumonia in methotrexate-receiving patients with rheumatoid arthritis  
**Kennosuke Mizushina**  
Division of Rheumatology, Toho University Ohashi Medical Center, Japan